Entity Details

Primary name PDE10_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionQ9Y233
EntryNamePDE10_HUMAN
FullNamecAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
TaxID9606
Evidenceevidence at protein level
Length779
SequenceStatuscomplete
DateCreated2000-05-30
DateModified2021-06-02

Ontological Relatives

GenesPDE10A

GO terms

Show/Hide Table
GOName
GO:0004114 3',5'-cyclic-nucleotide phosphodiesterase activity
GO:0004115 3',5'-cyclic-AMP phosphodiesterase activity
GO:0004118 cGMP-stimulated cyclic-nucleotide phosphodiesterase activity
GO:0005829 cytosol
GO:0006198 cAMP catabolic process
GO:0007165 signal transduction
GO:0007186 G protein-coupled receptor signaling pathway
GO:0010754 negative regulation of cGMP-mediated signaling
GO:0030552 cAMP binding
GO:0030553 cGMP binding
GO:0046069 cGMP catabolic process
GO:0046872 metal ion binding
GO:0047555 3',5'-cyclic-GMP phosphodiesterase activity

Subcellular Location

Show/Hide Table
Subcellular Location
Cytoplasm

Domains

Show/Hide Table
DomainNameCategoryType
IPR002073 3'5'-cyclic nucleotide phosphodiesterase, catalytic domainDomainDomain
IPR003018 GAF domainDomainDomain
IPR003607 HD/PDEase domainDomainDomain
IPR023088 3'5'-cyclic nucleotide phosphodiesteraseFamilyFamily
IPR023174 3'5'-cyclic nucleotide phosphodiesterase, conserved siteSiteConserved site
IPR029016 GAF-like domain superfamilyFamilyHomologous superfamily
IPR036971 3'5'-cyclic nucleotide phosphodiesterase, catalytic domain superfamilyFamilyHomologous superfamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
616921 OMIMDyskinesia, limb and orofacial, infantile-onset (IOLOD)An autosomal recessive, early-onset hyperkinetic movement disorder characterized by axial hypotonia, dyskinesia of the limbs and trunk, orofacial dyskinesia, drooling, and dysarthria. The severity of the hyperkinesis is variable. The disease is caused by variants affecting the gene represented in this entry.
616922 OMIMStriatal degeneration, autosomal dominant 2 (ADSD2)An autosomal dominant disorder characterized by striatal degeneration and dysfunction of basal ganglia, resulting in hyperkinesis. The disease is caused by variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB00201 CaffeineDrugbanksmall molecule
DB00975 DipyridamoleDrugbanksmall molecule
DB01113 PapaverineDrugbanksmall molecule
DB08383 4,5-bis(4-methoxyphenyl)-2-thiophen-2-yl-1H-imidazoleDrugbanksmall molecule
DB08384 2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinolineDrugbanksmall molecule
DB08386 2-{[4-(4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinolineDrugbanksmall molecule
DB08387 MardepodectDrugbanksmall molecule
DB08389 6,7-DIMETHOXY-4-[(3R)-3-(2-NAPHTHYLOXY)PYRROLIDIN-1-YL]QUINAZOLINEDrugbanksmall molecule
DB08391 PQ-10Drugbanksmall molecule
DB08811 TofisopamDrugbanksmall molecule
DB08814 TriflusalDrugbanksmall molecule
DB09283 TrapidilDrugbanksmall molecule

Interactions

3 interactions